Medtronic has locked in a pair of regulatory wins that should shape how its therapies are reimbursed in the years ahead. The American Medical Association approved new Category-I CPT codes covering the Altaviva system for urge incontinence and the Symplicity Spyral renal denervation platform for hypertension, replacing the interim Category-III codes that had governed both procedures. The catch: the new codes do not take effect until January 2028, leaving hospitals and physicians to plan around a transition window that stretches well past the current fiscal year.
Even with the delayed start date, the shift carries weight. Fixed reimbursement categories give clinics and doctors a predictable billing framework, a prerequisite the medical technology industry has long treated as essential for rolling out novel therapeutic approaches beyond the confines of clinical trials.
CardiacRead More
Ablation Platform Expands on Both Sides of the Atlantic
Regulatory momentum extends well past reimbursement. On September 30, Medtronic disclosed that its Affera Prism-2 mapping software had received both FDA clearance and the European CE mark. The same announcement confirmed CE certification for the PulseSelect ProxBox adapter, which pairs with proximity-indicator software. Together, these tools help cardiologists map and deliberately ablate cardiac tissue — additions that reinforce management’s push to build out the company’s electrophysiology platform and secure approvals in its most commercially significant markets.
The U.S. regulator cleared another device the following day. Medtronic’s ApexCut EM navigated blades for sinus surgery won 510(k) authorization, and the instruments can be linked to the Stealth AXiS ENT navigation system. Company officials expect the first clinical procedures in the United States during the remainder of 2026, contingent on the release of the corresponding navigation software.
MiniMed Spinoff Sets Final Exchange Ratio
Alongside the product milestones, Medtronic is pressing ahead with a portfolio overhaul. The company finalized the exchange ratio for the separation of its MiniMed Group diabetes unit: shareholders will receive 4.5939 MiniMed shares for each Medtronic common share they tender. The exchange offer and withdrawal rights are scheduled to expire at the end of October 9, 2026, unless an extension is announced.
Should investors sell immediately? Or is it worth buying Medtronic?
Leadership changes are accompanying the structural work. Felicia Kurz has taken charge of the cardiac ablation solutions division, according to media reports, a move that lands as the company integrates its expanded mapping and ablation portfolio.
Barclays Initiates With Neutral Stance
Against that operational backdrop, Barclays began covering Medtronic on Tuesday with an Equal-Weight rating and a $95 price target. Analyst Christopher Pasquale’s assessment reflects a wait-and-see posture toward a company working through multiple strategic and regulatory transitions at once. The firm pointed to softer conditions across the broader medical technology sector, while holding out the prospect of stabilizing fundamentals in 2027.
Trading has been subdued. Medtronic shares closed the prior session at EUR 76.56 before edging up to EUR 76.40 in pre-market activity, and the stock added 0.2% in today’s session to reach EUR 76.68. The company’s market capitalization stands at EUR 99.52 billion.
What matters for investors now is how quickly the formal billing codes and software clearances translate into measurable revenue growth across Medtronic’s medical technology divisions — a conversion that, on the reimbursement side at least, remains more than two years away.
Ad
Medtronic Stock: Buy or Sell?! New Medtronic Analysis from October 8 delivers the answer:
The latest Medtronic figures speak for themselves: Urgent action needed for Medtronic investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 8.
Medtronic: Buy or sell? Read more here...
